MeSH term
Frequency | Condition_Probility | Aged | 4 | 0.0 |
Humans | 54 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Balloon Dilatation/adverse effects/*instrumentation | 2 | 4.0 |
Esophageal and Gastric Varices/therapy | 2 | 4.0 |
Esophagus/*injuries/radiography | 2 | 4.0 |
Fatal Outcome | 2 | 0.0 |
Female | 10 | 0.0 |
Foreign Bodies/*radiography | 2 | 4.0 |
Gastrointestinal Hemorrhage/therapy | 2 | 4.0 |
*Medical Errors | 2 | 4.0 |
Pleural Cavity/*radiography | 2 | 4.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Animals | 21 | 0.0 |
Cells, Cultured | 13 | 0.0 |
*Drosophila Proteins | 20 | 1.0 |
Membrane Glycoproteins/genetics/*metabolism | 7 | 4.0 |
Mice | 12 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Receptors, Cell Surface/genetics/*metabolism | 7 | 5.0 |
Research Support, Non-U.S. Gov't | 36 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 23 | 0.0 |
Signal Transduction | 5 | 0.0 |
Cell Line | 15 | 0.0 |
Male | 5 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Membrane Glycoproteins/genetics/*physiology | 3 | 4.0 |
Mice, Inbred C3H | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Receptors, Cell Surface/genetics/*physiology | 3 | 5.0 |
*Signal Transduction | 3 | 0.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Macrophages/metabolism | 4 | 1.0 |
Monocytes/metabolism | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
Transfection | 11 | 0.0 |
Gene Expression | 3 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Cell Line, Transformed | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Cytokines/biosynthesis | 3 | 0.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Receptors, Cell Surface/physiology | 3 | 2.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
Dimerization | 3 | 0.0 |
NF-kappa B/metabolism | 8 | 1.0 |
Precipitin Tests | 2 | 0.0 |
Antigens, CD14/biosynthesis | 2 | 3.0 |
Membrane Glycoproteins/*physiology | 4 | 1.0 |
Receptors, Cell Surface/*physiology | 4 | 1.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Receptors, Cell Surface/*genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
*Immunity, Natural | 2 | 3.0 |
Signal Transduction/immunology | 2 | 0.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Receptors, Cell Surface/*immunology | 2 | 2.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Receptors, Cell Surface/*metabolism | 4 | 0.0 |
Ligands | 4 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Zymosan/pharmacology | 2 | 2.0 |
Amino Acid Sequence | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Base Sequence | 3 | 0.0 |
Monocytes/immunology | 2 | 0.0 |
Adult | 3 | 0.0 |
Genome, Human | 2 | 0.0 |
Middle Aged | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Immunity, Natural | 4 | 1.0 |
Species Specificity | 3 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
Spleen/immunology | 2 | 1.0 |
